# Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer

> **NCT00066443** · PHASE1,PHASE2 · COMPLETED · sponsor: **NCIC Clinical Trials Group** · enrollment: 93 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** pegfilgrastim
- **DRUG:** docetaxel
- **DRUG:** epirubicin hydrochloride

## Key facts

- **NCT ID:** NCT00066443
- **Lead sponsor:** NCIC Clinical Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-11-03
- **Primary completion:** 2010-01-06
- **Final completion:** 2014-01-16
- **Target enrollment:** 93 (ACTUAL)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00066443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00066443, "Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00066443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*